Fennec Pharmaceuticals Company Insiders
FENC Stock | USD 8.45 0.30 3.43% |
About 89 percent of Fennec Pharmaceuticals' insiders are activelly selling. The analysis of the overall insider sentiment regarding Fennec Pharmaceuticals suggests that quite a large number of insiders are panicking. Fennec Pharmaceuticals employs about 32 people. The company is managed by 12 executives with a total tenure of roughly 31 years, averaging almost 2.0 years of service per executive, having 2.67 employees per reported executive.
Rostislav Raykov CEO CEO, Director |
Insider Sentiment 11
Mostly Selling
Selling | Buying |
Latest Trades
2025-07-07 | Chris A Rallis | Disposed 1119 @ 8.71 | View | ||
2025-07-03 | Rosty Raykov | Disposed 10000 @ 8.61 | View | ||
2025-06-05 | Rosty Raykov | Disposed 10000 @ 7.78 | View | ||
2025-05-19 | Jeffrey S Hackman | Acquired 13965 @ 6.99 | View | ||
2025-05-16 | Jeffrey S Hackman | Acquired 1035 @ 6.75 | View | ||
2025-05-05 | Rosty Raykov | Disposed 10000 @ 6.31 | View | ||
2025-04-04 | Rosty Raykov | Disposed 10000 @ 5.25 | View | ||
2025-03-05 | Rosty Raykov | Disposed 10000 @ 6.79 | View | ||
2025-02-14 | Chris A Rallis | Disposed 1186 @ 6.82 | View | ||
2025-02-05 | Rosty Raykov | Disposed 10000 @ 6.66 | View | ||
2025-01-06 | Rosty Raykov | Disposed 10000 @ 6.08 | View | ||
2024-12-05 | Rosty Raykov | Disposed 796 @ 6.04 | View | ||
2024-12-02 | Chris A Rallis | Disposed 6409 @ 6.14 | View | ||
2024-11-04 | Rosty Raykov | Disposed 2431 @ 4.31 | View | ||
2024-10-08 | Chris A Rallis | Disposed 1406 @ 4.53 | View | ||
2024-10-01 | Rosty Raykov | Disposed 2431 @ 4.94 | View | ||
2024-08-01 | Rosty Raykov | Disposed 2431 @ 6.25 | View |
Monitoring Fennec Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fennec Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. Fennec Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Fennec Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Fennec will maintain a workforce of about 30 employees by August 2025.Fennec Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.1296) % which means that it has lost $0.1296 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.0559) %, meaning that it created substantial loss on money invested by shareholders. Fennec Pharmaceuticals' management efficiency ratios could be used to measure how well Fennec Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Fennec Pharmaceuticals' Return On Equity is projected to increase significantly based on the last few years of reporting. At present, Fennec Pharmaceuticals' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 46.3 M, whereas Net Tangible Assets are projected to grow to (2.8 M).The current year's Common Stock Shares Outstanding is expected to grow to about 28.7 M, whereas Net Loss is projected to grow to (20.3 M).
Fennec Pharmaceuticals Workforce Comparison
Fennec Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 694. Fennec Pharmaceuticals holds roughly 32.0 in number of employees claiming about 5% of equities under Health Care industry.
Fennec Pharmaceuticals Profit Margins
The company has Profit Margin (PM) of (0.47) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.09) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.09.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.89 | 0.933 |
|
|
Fennec Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fennec Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fennec Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Fennec Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-09-01 | 0.25 | 1 | 4 | 2,127 | 413,246 |
2025-06-01 | 3.0 | 15 | 5 | 176,972 | 54,887 |
2025-03-01 | 3.0 | 18 | 6 | 437,411 | 33,178 |
2024-12-01 | 1.3 | 13 | 10 | 513,195 | 67,884 |
2024-09-01 | 1.5556 | 14 | 9 | 500,684 | 131,297 |
2024-06-01 | 1.0952 | 23 | 21 | 797,223 | 402,884 |
2024-03-01 | 0.1667 | 1 | 6 | 4,329 | 64,393 |
2023-12-01 | 0.7273 | 8 | 11 | 308,842 | 322,121 |
2023-09-01 | 0.6 | 3 | 5 | 221,946 | 31,550 |
2023-06-01 | 1.0 | 7 | 7 | 131,700 | 52,744 |
2023-03-01 | 5.0 | 5 | 1 | 379,166 | 2,177 |
2022-12-01 | 0.1111 | 1 | 9 | 4,762 | 53,141 |
2022-09-01 | 2.0 | 4 | 2 | 115,277 | 23,431 |
2020-09-01 | 0.875 | 7 | 8 | 752,922 | 372,911 |
2019-12-01 | 1.0 | 1 | 1 | 20,000 | 20,000 |
2019-09-01 | 1.0 | 1 | 1 | 175,000 | 175,000 |
2018-03-01 | 0.069 | 2 | 29 | 150,000 | 984,445 |
2017-06-01 | 1.0 | 8 | 8 | 3,000 | 235,400 |
2016-12-01 | 18.0 | 18 | 1 | 45,600 | 35,545 |
2016-09-01 | 9.0 | 18 | 2 | 66,600 | 225,000 |
2016-06-01 | 4.0 | 12 | 3 | 108,850 | 40,984 |
2015-12-01 | 17.0 | 34 | 2 | 135,200 | 54,062 |
2015-06-01 | 8.0 | 8 | 1 | 26,360 | 2,173 |
2015-03-01 | 14.0 | 14 | 1 | 63,200 | 1,992 |
2014-12-01 | 7.6 | 38 | 5 | 187,934 | 56,960 |
2014-09-01 | 2.0 | 2 | 1 | 3,332 | 1,792 |
2010-09-01 | 3.0 | 6 | 2 | 0.00 | 647,922 |
2010-06-01 | 0.75 | 3 | 4 | 400,000,000 | 83,008,000 |
2007-06-01 | 11.0 | 11 | 1 | 7,190,000 | 0.00 |
Fennec Pharmaceuticals Notable Stakeholders
A Fennec Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Fennec Pharmaceuticals often face trade-offs trying to please all of them. Fennec Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Fennec Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Rostislav Raykov | CEO, Director | Profile | |
Jeffrey Hackman | CEO Director | Profile | |
Lei Fang | President Inc | Profile | |
Adrian Haigh | Independent Director | Profile | |
Mark Meier | VP Commercial | Profile | |
Christiana MBA | Chief Officer | Profile | |
Mark Gowland | Controller | Profile | |
Terry Evans | Chief Officer | Profile | |
Robert Andrade | Chief Officer | Profile | |
Dr MS | Chief Officer | Profile | |
Anne McKay | Regulatory Consultant | Profile | |
Alexander MS | Consultant | Profile |
About Fennec Pharmaceuticals Management Performance
The success or failure of an entity such as Fennec Pharmaceuticals often depends on how effective the management is. Fennec Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Fennec management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Fennec management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.01) | (0.01) | |
Return On Capital Employed | 0.07 | 0.07 | |
Return On Assets | (0.01) | (0.01) | |
Return On Equity | 0.08 | 0.08 |
Please note, the presentation of Fennec Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Fennec Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Fennec Pharmaceuticals' management manipulating its earnings.
Fennec Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Fennec Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Fennec Pharmaceuticals within its industry.Fennec Pharmaceuticals Manpower Efficiency
Return on Fennec Pharmaceuticals Manpower
Revenue Per Employee | 1.5M | |
Revenue Per Executive | 4M | |
Net Loss Per Employee | 2.2K | |
Net Loss Per Executive | 5.8K | |
Working Capital Per Employee | 1.2M | |
Working Capital Per Executive | 3.1M |
Complementary Tools for Fennec Stock analysis
When running Fennec Pharmaceuticals' price analysis, check to measure Fennec Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fennec Pharmaceuticals is operating at the current time. Most of Fennec Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Fennec Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fennec Pharmaceuticals' price. Additionally, you may evaluate how the addition of Fennec Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |